Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Piotr Rutkowski et al.|The Lancet|2012Cited by 1.4k
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyondDaniela Di Lisi, Giuseppina Novo, Rosalinda Madonna et al.|International Journal of Cardiology|2016Cited by 73